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Amyotrophic lateral sclerosis
Matthew C Kiernan, Steve Vucic, Benjamin C Cheah, Martin R Turner, Andrew Eisen, Orla Hardiman, James R Burrell, Margaret C Zoing
Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In 
this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop 
the disorder, and discuss why all cases of ALS are not the same. In the 150 years since Charcot originally described 
ALS, painfully slow progress has been made towards answering these questions. We focus on what is known about 
ALS and where research is heading—from the small steps of extending longevity, improving therapies, undertaking 
clinical trials, and compiling population registries to the overarching goals of establishing the measures that guard 
against onset and ﬁ nding the triggers for this neurodegenerative disorder.
Introduction
Since the 1990s, there has been growing scientiﬁ c and 
clinical interest in amyotrophic lateral sclerosis (ALS). 
Advances in our understanding of the glutamate 
neurotransmitter system and the discovery of causal genes 
linked to the development of familial ALS have stimulated 
research interest, problems associated with clinical 
heterogeneity have been identiﬁ ed, and survival in ALS is 
now understood to be dependent on several factors, 
including clinical presentation (phenotype), rate of disease 
progression, early presence of respiratory failure, and the 
nutritional status of patients.
Extending life expectancy in ALS seems to be dependent 
on improving our understanding of its pathogenesis, 
which will lead to the development of early and speciﬁ c 
diagnostic methods. There is a crucial need to formulate 
therapies that not only slow disease progression, but also 
deal with the secondary consequences of malnutrition 
and respiratory failure. At present, no deﬁ nitive diagnostic 
test or biomarker for ALS exist, and neurologists rely on 
only clinical criteria for diagnosis. The development of 
novel biomarkers to objectively assess disease progression 
holds the promise of greatly reﬁ ning therapeutic trial 
design and reducing trial costs. Furthermore, the power 
of population registries is being increasingly recognised 
as an essential adjunct to improved clinical assessment 
techniques. These collaborative endeavours will inevitably 
lead to a better understanding of ALS and its often 
unpredictable progression, and will lead to the 
development of guidelines for improved care of patients. 
In this Seminar, we provide an up-to-date overview of the 
key developments across the ALS specialty.
Epidemiology and molecular genetics
Several factors have complicated epidemiological studies 
in ALS, including determination of a speciﬁ c date of 
disease onset and the potentially long duration between 
onset of pathological changes and manifestation of 
clinical disease. This prodomal period between disease 
onset and presentation of symptoms possibly indicates 
the redundancy of neuronal populations. As a 
consequence, a range of epidemiological studies with 
rigorous designs and the use of unbiased patient cohorts 
have provided varying levels of evidence in support of 
diﬀ erent causative mechanisms of disease.1,2 Population-
based studies have established that the incidence of ALS 
in Europe is fairly uniform at 2·16 per 100 000 person-
years.3 Although ALS aﬀ ects people worldwide, an exact 
incidence of this disease is not yet known.4 Men have a 
higher incidence of disease (3·0 per 100 000 person-years; 
95% CI 2·8–3·3) than do women (2·4 per 100 000 person-
years; 95% CI 2·2–2·6), although the incidence between 
men and women is about the same in familial disease. 
The overall population-based lifetime risk of ALS is 
1:400 for women and 1:350 for men. Peak age at onset is 
58–63 years for sporadic disease and 47–52 years for 
familial disease. Incidence decreases rapidly after 80 years 
of age.3
Although the ALS phenotype might seem similar 
across populations, there are subtle diﬀ erences in clinical 
presentation across European registries.3 There is 
evidence from population-based studies that suggest that 
ALS is less common in individuals of mixed ancestral 
origin than in individuals of Spanish origin.4 In a 
population-based mortality study from Cuba,5 disease 
rates were 60% lower than in European and North 
American populations, lending support to previous 
observations of reduced frequency of ALS in those of 
Hispanic origin in North America.
About 5–10% of ALS is familial, with a Mendelian 
pattern of inheritance. To date, 13 genes and loci of 
major eﬀ ect have been identiﬁ ed, many since 2009.6,7 Of 
the known genes, mutations in SOD1 (encodes for 
Search strategy and selection criteria
We searched Medline (1966, to December, 2009), EmBase 
(1980, to December, 2009), and the Cochrane Library using 
the search terms “amyotrophic lateral sclerosis” or “motor 
neurone disease” in combination with “diagnosis”, 
“epidemiology”, “fronto-temporal dementia”, “imaging”, 
“neurophysiology”, “management”, and “neuroprotection”. 
Further articles were included from reference lists, review 
articles, and major textbook chapters. Abstracts and reports 
from relevant meetings were also included. The ﬁ nal reference 
list was generated on the basis of originality and relevance to 
the topics covered in this Seminar. Emphasis was placed on 
publications from the past 5 years, but did not exclude 
commonly referenced and highly regarded older publications. 
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copper/zinc ion-binding superoxide dismutase), 
TARDBP (also known as TDP-43; encodes for TAR DNA 
binding protein), FUS (encodes fusion in sarcoma), 
ANG (encodes angiogenin, ribonuclease, RNase A 
family, 5), and OPTN (encodes optineurin) cause a 
typical clinical phenotype. Mutations in SOD1 induce a 
toxic gain of function, although the pathophysiology 
remains unclear. Both TDP-438 and FUS9,10 (also known 
as TLS [translated in liposarcoma]) are multifunctional 
proteins involved in gene expression and regulation, 
including transcription, RNA splicing, transport, and 
translation. FUS and TDP-43 are also involved in the 
processing of small regulatory RNAs (microRNAs) and 
in RNA maturation and splicing. ANG is a hypoxia-
responsive gene, which regulates RNA transcription.11 
OPTN is a causative gene of primary open-angle 
glaucoma. ALS-causing mutations of OPTN abolish the 
inhibition of activation of NFκB, and change the 
cytoplasmic distribution of optineurin.
Mutations in SOD1 account for 20% of familial ALS12 
and 5% of apparently sporadic disease. Mutations in 
TARDBP account for 5–10% of familial ALS, mutations in 
FUS for 5%, and mutations in ANG for about 1%. 
The remaining 90% of people diagnosed with ALS are 
classiﬁ ed as having sporadic disease. For these patients, 
results from family aggregation studies have identiﬁ ed 
an overlap between ALS and common neurodegenerative 
disorders, suggesting the existence of susceptibility genes 
that might increase the overall risk of neurodegeneration 
among relatives.13 However, attempts to establish the 
complex genetic basis for sporadic ALS by identifying 
susceptibility genes have had little success. Results from 
candidate gene studies have identiﬁ ed several 
susceptibility genes,7 although the relative contribution 
of every identiﬁ ed “at risk” gene rarely exceeds an odds 
ratio of 2·0, and the mechanism by which risk is 
conferred is not known.
Despite the disappointing ﬁ ndings in several recent 
genome-wide association studies of sporadic ALS,4 a few 
possible genes have been identiﬁ ed. The main problem 
has been low power due to small sample sizes, with 
candidates being accordingly diﬃ  cult to replicate in a 
second population.7 The recent identiﬁ cation of two new 
susceptibility genes through collaborative research14 
suggests that further genes and pathways could be 
identiﬁ ed with increasingly eﬀ ective cooperation 
between research groups. However, the poor track 
record of whole-genome association studies has led to a 
reconsideration of the “common disease, common 
variant” hypothesis in favour of a “common disease, 
multiple rare variant” hypothesis.
Clinical phenotypes and prognosis
The varied presentations of ALS15 are also crucial to 
the understanding and development of measures of 
disease progression.16 The identiﬁ cation of speciﬁ c 
phenotypes has important implications for patients, 
particularly with regards to prognosis and survival, but 
also for their enrolment in clinical trials.
The main presentations of ALS include: (1) limb-onset 
ALS with a combination of upper and lower motor 
neuron (UMN and LMN) signs in the limbs; (2) bulbar-
onset ALS, presenting with speech and swallowing 
diﬃ  culties, and with limb features developing later in the 
course of the disease (ﬁ gure 1); (3) the less common 
primary lateral sclerosis with pure UMN involve-
ment; and (4) progressive muscular atrophy, with pure 
LMN involvement.19
The clinical hallmark of ALS is the presence of UMN 
and LMN features involving brainstem and multiple 
spinal cord regions of innervation. Patients can present 
with bulbar-onset disease (about 25%) or limb-onset 
disease (about 70%), or with initial trunk or respiratory 
involvement (5%), subsequently spreading to involve 
other regions.20 Atypical modes of presentation can include 
weight loss, which is an indicator of a poor prognosis, 
cramps and fasciculations in the absence of muscle 
Figure 1: Clinical features of muscles wasting in a patient with ALS 
Proximal and symmetrical upper limb wasting (A) results in an inability to lift arms against gravity (“man-in-the-
barrel” or ﬂ ail-arm variant ALS). Note the recessions above and below the scapular spine (B), indicating wasting of 
supraspinatus and infraspinatus muscles, as well as substantial loss of deltoid muscle. As a consequence, the 
glenohumeral joint becomes prominent, and prone to subluxation. (C) Disproportionate wasting of the thenar 
muscles combined with the ﬁ rst dorsal interossei, the so-called “split-hand”, is a typical feature in ALS.17 Although the 
mechanisms underlying this disproportionate wasting of hand muscles are unclear, a corticomotoneuronal origin has 
been proposed.17 Speciﬁ cally, the thenar muscles and ﬁ rst dorsal interossei receive more extensive corticospinal 
connections and thereby might be prone to glutamate-mediated excitotoxicity.18 (D) Substantial wasting of the 
tongue muscles in bulbar-onset ALS. Note the absence of palatal elevation present on vocalisation. Diﬃ  culty with 
mouth opening and dysphagia might require supplementary feeding through a percutaneous endoscopic 
gastrostomy. In further support of a corticomotoneuronal hypothesis, the tongue is often disproportionately aﬀ ected 
in comparison to other oropharyngeal musculature in patients with bulbar-onset ALS. As with the thenar muscles in 
the hand, the tongue receives more extensive cortical input than other muscle groups in the oropharyngeal area. 
ALS=amyotrophic lateral sclerosis.
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C D
Seminar
944 www.thelancet.com   Vol 377   March 12, 2011
weakness, emotional lability, and frontal lobe-type 
cognitive dysfunction.21
In terms of presentation, UMN disturbance involving 
the limbs leads to spasticity, weakness, and brisk deep 
tendon reﬂ exes. By contrast, LMN limb features include 
fasciculations, wasting, and weakness. Bulbar UMN 
dysfunction results in spastic dysarthria, which is 
characterised by slow, laboured, and distorted speech, 
often with a nasal quality.22 The gag and jaw jerk can 
be pathologically brisk. Bulbar LMN dysfunction can 
be identiﬁ ed by tongue wasting, weakness, and 
fasciculations, accompanied by ﬂ accid dysarthria and 
later dysphagia. Flaccid dysarthria results in nasal 
speech caused by palatal weakness, hoarseness, and a 
weak cough.22
ALS is relentlessly progressive—50% of patients die 
within 30 months of symptom onset and about 20% of 
patients survive between 5 years and 10 years after 
symptom onset.23 Older age at symptom onset, early 
respiratory muscle dysfunction, and bulbar-onset disease 
are associated with reduced survival, whereas limb-onset 
disease, younger age at presentation, and longer diagnostic 
delay are independent predictors of pro longed survival.23
Some ALS subtypes tend to lead to a better prognosis. 
Speciﬁ cally, ﬂ ail-limb variant ALS (ﬁ gure 1A, ﬁ gure 1B) 
and progressive muscular atrophy, both predominantly 
LMN forms, are characterised by slower progression 
than other forms of ALS.23,24 In the pure bulbar palsy 
phenotype, which typically aﬀ ects women older than 
65 years of age with disease remaining localised to 
oropharyngeal musculature and with UMN features 
predominating,23 the prognosis varies from 2–4 years. 
Additionally, patients with primary lateral sclerosis 
progress more slowly than do patients with classic 
Figure 2: Cellular and molecular processes mediating neurodegeneration in ALS
The mechanisms underlying neurodegeneration in ALS are multifactorial and operate through inter-related molecular and genetic pathways. Speciﬁ cally, neurodegeneration in ALS might result 
from a complex interaction of glutamate excitoxicity, generation of free radicals, cytoplasmic protein aggregates, SOD1 enzymes, combined with mitochondrial dysfunction, and disruption of 
axonal transport processes through accumulation of neuroﬁ lament intracellular aggregates. Mutations in TARDBP and FUS result in formation of intracellular aggregates, which are harmful to 
neurons. Activation of microglia results in secretion of proinﬂ ammatory cytokines, resulting in further toxicity. Ultimately, motor neuron degeneration occurs through activation of 
calcium-dependent enzymatic pathways. ALS=amyotrophic lateral sclerosis.
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ALS.19,23 A deﬁ nite diagnosis of primary lateral sclerosis 
should be delayed for at least 4 years from disease onset, 
given that development of LMN signs can occur even if 
the initial presentation appears that of a pure spastic 
syndrome.25 Distinguishing these phenotypes from the 
typical ALS phenotype has implications for clinical trials 
of putative disease-modifying therapies.
Fatigue and reduced exercise capacity are common 
symptoms in ALS26 and, ultimately, most patients need 
assistance with activities of daily living. Dysphagia 
develops in most patients with ALS, with consequent 
weight loss and malnutrition associated with poor 
prognosis.27 Respiratory compromise eventually develops 
in most cases of ALS, leading to exertional dyspnoea, 
orthopnoea, hypoventilation with resultant hypercapnia, 
and early morning headaches.28 Death becomes imminent 
once patients develop dyspnoea at rest. Progressive 
weakening of the respiratory muscles leads to respiratory 
failure, often precipitated by pneumonia.
Overlap with frontotemporal dementia
The recent identiﬁ cation of TDP-43-positive ubiquit inated 
cytoplasmic inclusions in almost all cases of ALS, and 
more than half of patients with frontotemporal 
dementia (FTD), has rekindled interest in the overlap 
between these progressive neurodegenerative syndromes.29 
Although reported in early descriptions, overt cognitive 
symptoms and frank dementia were previously thought to 
be uncommon symptoms of ALS. Conversely, a few 
patients with FTD develop ALS.30 Familial clustering of 
both disorders is also well recognised, with cases of FTD 
or ALS or coincident FTD-ALS presenting in families. The 
genes that cause these familial clusters are not yet known, 
but results from linkage studies have identiﬁ ed a common 
locus on chromosome 9.31–35
Cognitive deﬁ cits might initially have a subtle 
appearance and are often overlooked, but with appropriate 
cognitive and neuropsychological assess ment, 20–50% of 
patients with ALS fulﬁ l the consensus criteria for probable 
or deﬁ nite FTD.36 The most commonly encountered 
deﬁ cits involve executive function,37 either aﬀ ecting 
language or personality, with the cognitive proﬁ le most 
closely resembling that of behavioural-variant FTD. In 
terms of clinical implications, problems with judgment, 
impulsivity, and a general deterioration in the ability to 
undertake routine daily tasks can develop into diﬃ  cult 
problems with management of patients.38 Impaired verbal 
ﬂ uency, which is more prominent in patients with 
pseudobulbar disease, inevitably hinders the simple task 
of patients being able to communicate their needs. 
Cognitive, and particularly executive dysfunction, can also 
adversely aﬀ ect patient compliance with treatment, 
decision-making abilities, and potentially raise ethical 
and medico-legal concerns.37
In further support of overlap between these two 
diseases, structural abnormalities, and speciﬁ cally 
frontotemporal atrophy, have been identiﬁ ed by voxel-
based morphometry MRI in patients with ALS and 
FTD-ALS. Bilateral atrophy of the motor and premotor 
cortices can develop,30,39 although patients with FTD-ALS 
typically have more severe frontotemporal atrophy than 
do patients with ALS alone.31,39 From a functional 
perspective, frontotemporal hypometabolism has been 
characterised in patients with ALS and FTD-ALS by 
use of 2-¹⁸ﬂ uoro-2-deoxy-D-glucose PET.33 This fronto-
temporal atrophy seems to be associated with neuronal 
loss and cortical gliosis on post-mortem pathology. As 
for most patients with sporadic ALS, intraneuronal 
inclusions (TDP-43-positive) are present in half of 
patients with FTD.32,40 FUS-positive inclusions have been 
recently identiﬁ ed in patients with ubiquitin-positive, 
TDP-43-negative FTD and in patients with familial ALS 
caused by mutations in FUS39,40—further emphasising 
the pathological overlap between ALS and FTD.
Pathophysiological mechanisms
The pathophysiological mechanisms underlying the 
development of ALS seem multifactorial (ﬁ gure 2), with 
emerging evidence of a complex interaction between 
genetic and molecular pathways.41–43 ALS might be an 
Panel 1: Controversy in ALS—where does the disease begin?
• Despite Charcot’s initial observation of concomitant UMN and LMN pathological 
changes in ALS, the question of where ALS begins has not been established. 
Resolution of this question might enhance the understanding of the pathophysiology 
of ALS and has diagnostic and therapeutic importance.
• The “dying-forward” hypothesis proposes that ALS is mainly a disorder of 
corticomotoneurons, which connect monosynaptically with anterior horn cells, 
mediating anterograde degeneration of anterior horn cells via glutamate 
excitotoxicity.
• Support for a dying-forward hypothesis includes:
• Results from transcranial magnetic stimulation studies documenting that cortical 
hyperexcitability is an early feature in patients with sporadic ALS and precedes the 
clinical onset of familial ALS.
• Clinical observations that: (1) motor neurons without a monosynaptic connection 
with corticomotoneurons, such as the oculomotor, abducens, and Onuf’s nuclei, 
are typically spared in ALS; (2) the absence of a naturally occurring animal model of 
ALS is ascribed to a paucity of corticomotoneuronal-anterior horn cell 
connections; and (3) pure LMN forms of ALS are rare, whereas subclinical UMN 
involvement is invariably detected with transcranial magnetic stimulation studies.
• The “dying-back” hypothesis proposes that ALS begins within the muscle cells or at 
the neuromuscular junction. Speciﬁ cally, there is deﬁ ciency of a motor neurotrophic 
hormone, which is normally released by postsynaptic cells and retrogradely 
transported up the presynaptic axon to the cell body where it exerts its eﬀ ects.
• Support for the dying-back hypothesis includes:
• Observations that synaptic denervation precedes the onset of motor neuron 
degeneration.
• Synaptic denervation is mediated by accumulation of mutant SOD1 protein in 
Schwann cells.
• By contrast with the dying-forward and dying-back hypotheses, some investigators 
have proposed that UMN and LMN degeneration occur independently.
ALS=amyotrophic lateral sclerosis. LMN=lower motor neuron. UMN=upper motor neuron.
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adult manifestation of a developmental disorder of the 
human motor system. Speciﬁ cally, in a Swedish case-
control study,1 low maternal age and high maternal age, 
and exposure to younger siblings, were associated with 
increased risk of developing ALS. Additionally, the 
development of the human motor system might 
potentially be perturbed during childhood by increased 
exposure to childhood infections, as occurs in families 
with young children. Various environmental risk factors 
for ALS have also been suggested, including a lifetime 
of intensive sport or physical exertion44 and active service 
in the US armed forces.45 In a retrospective study of 
football players from the Italian professional leagues, 
the standardised morbidity ratios were increased for 
development of ALS, particularly younger-onset 
disease.46 For unknown reasons, footballers who played 
for more than 5 years, particularly in an active midﬁ eld 
position, were at highest risk of developing ALS. A 
cluster of ALS cases has also been reported in amateur 
football players from England.47
With regards to smoking, cigarettes might have a dose-
dependent eﬀ ect on the subsequent development of 
ALS.48 Neurotoxins, including β-methyl-amino-L-alanine, 
were associated with the development of an epidemic of 
ALS-Parkinson’s disease on the island of Guam.49 This 
neurotoxic aminoacid was concentrated in the brains of 
patients with ALS-Parkinson’s disease and entered the 
human food chain by consumption of ﬂ ying foxes. These 
bats, a delicacy of native Guamanians, the Chamorro, 
feed on cycad seeds that have high concentrations of 
β-methyl-amino-L-alanine.49
No clear consensus has emerged to link SOD1 mutations 
to the premature death of motor neurons. Current 
understanding links genetic mutations to a toxic gain of 
function of the SOD1 enzyme,41 with generation of free 
radicals that eventually leads to cell injury and death.50–53 
Additionally, SOD1 mutations induce conformational 
instability and misfolding of the SOD1 peptide, resulting 
in formation of intracellular aggregates51,54 that inhibit 
normal proteosomic function, disrupting axonal transport 
systems and vital cellular functions.50,51,55
Glutamate-induced excitotoxicity has been implicated 
in ALS pathogenesis. Glutamate is the main excitatory 
neurotransmitter in the CNS, and binds to ionotropic 
N-methyl-D-aspartate (NMDA) receptors and α-amino-3-
hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) 
receptors on the postsynaptic membrane.56,57 Excessive 
activation of these postsynaptic receptors by glutamate, 
known as glutamate-induced excitotoxicity, can incite 
neurodegeneration through activation of calcium-
dependent enzymatic pathways.58,59 Glutamate-induced 
excitotoxicity can also result in generation of free 
radicals, which in turn can cause neurodegeneration by 
damaging intracellular organelles and upregulating 
proinﬂ ammatory mediators.60,61 
The mechanism by which glutamate-induced 
excitotoxicity mediates motor neuron degeneration in 
human beings remains unclear (panel 1, ﬁ gure 3). A 
so-called “dying-forward” process has been proposed, 
whereby UMN mediate anterograde degeneration of 
LMN by glutamate-induced excitotoxic processes.62,63
In addition to glutamate-induced excitotoxicity, 
structural abnormalities of mitochondria, dysfunction of 
the sodium/potassium ion pump, autophagy, and 
disrupted axonal transport systems have all been 
implicated in the pathogenesis of ALS.64–70 Non-neuronal 
cells, such as astrocytes and microglia, might also directly 
contribute to neurodegeneration through mechanisms 
including insuﬃ  cient release of neurotrophic factors, 
secretion of neurotoxic mediators, and modulation of 
glutamate receptor expression (known as non-cell 
autonomous neurodegeneration).71
Of further relevance, TDP-43 was recognised as a major 
component of ubiquitinated cytoplasmic protein 
aggregates in almost all patients with sporadic ALS, 
but not in the nucleus, as in normal neurons. 
Although there were questions about whether such 
aggregates triggered neurodegeneration in ALS, 
mutations in TARDBP were reported in 3% of familial 
ALS and 1·5% of patients with sporadic ALS, suggesting 
that TDP-43 aggregates have a central role in trigger-
ing ALS.8,72 Evidence for the pathogenicity of 
Figure 3: The “dying-forward” and “dying-back” hypotheses 
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TARDBP mutations was suggested when mutations 
identi ﬁ ed in highly conserved regions of DNA were not 
evident in controls, and segregated with the disease.8,72 
Given that TDP-43 binds both DNA and RNA, 
mutations in TARDBP could result in dysregulation of 
RNA processing.
Identiﬁ cation of FUS mutations on chromosome 16 
associated with familial forms of ALS lends further 
support to this theory. FUS aggregates were not evident 
in patients with pathological changes in TDP-43 or 
SOD1, indicating a novel disease pathway.10 Although the 
identiﬁ cation of a causative eﬀ ect between mutations in 
the TARDBP and FUS genes and ALS was a major leap 
in understanding ALS pathogenesis, several factors need 
to be resolved. Do mutations in these DNA/RNA-binding 
proteins indicate a toxic gain or loss of function?73 Does 
neurotoxicity result from the misfolded proteins 
overwhelming the cells’ protein surveillance pathways or 
from sequestration of vital proteins and genomic 
material by TDP-43 and FUS aggregates? And what is 
the association between previously established patho-
physiological mechanisms and the TDP-43 and 
FUS proteins?
Diagnosis
Without a diagnostic test for ALS, clinicians mostly rely 
on identifying the combination of UMN and LMN signs 
in the same body region, with subsequent evidence of 
disease progression to other regions. The El Escorial 
criteria,74 revised in 1997,75 use a combination of UMN 
and LMN signs to establish levels of diagnostic certainty. 
Clinical trial investigators have tended to enrol patients 
with either probable or deﬁ nite ALS according to the 
El Escorial criteria, highlighting their universality, 
although inclusion of these diagnostic features as 
enrolment criteria might be argued as restrictive.76 
Furthermore, these criteria can have poor sensitivity, 
particularly in the early stages of ALS when patients are 
most likely to beneﬁ t from therapeutic intervention.77 
Because of these criticisms, the criteria have been 
modiﬁ ed to help early diagnosis78 and to optimise 
levels of diagnostic certainty, important in the clinical 
trial setting.79
There is often a long delay before a deﬁ nitive diagnosis 
is reached, partly because of the insidious onset of 
symptoms, with the median time to diagnosis of about 
14 months.80 Unusual clinical presentations, a low index 
of suspicion, and misinterpretation of neurophysio-
logical or neuroradiological ﬁ ndings are common causes 
of diagnostic uncertainty.15 Unfortunately, diagnostic 
delay can lead to use of inappropriate therapies, a 
delay in starting appropriate pharmacological and 
symptomatic therapies, and problems in dealing with 
psycho social factors.
The diagnosis of ALS is devastating for the patient and 
family members, and must be handled sensitively. Patients 
and family members can carry the emotional burden of an 
insensitively delivered diagnosis for the entire disease 
course, and initial indecision about the diagnosis in 
atypical cases can delay the process of accepting the 
terminal prognosis of the disease. Scheduling a follow-
up appointment soon after diagnosis is beneﬁ cial to 
answer questions not dealt with during the initial 
consultation and can help provide further information 
about support networks, which are well established in 
most developed nations.81
Although rare, the existence of several disorders 
that mimic ALS necessitates a thorough diagnostic 
Panel 2: Diﬀ erential diagnosis of ALS and appropriate investigations
Disorders of motor neurons
• Spinal muscular atrophy (SMN gene deletion assay)
• X-linked spinobulbar muscular atrophy (Kennedy’s disease; increased CAG repeats in 
DNA from blood)
• Poliomyelitis or post-polio syndrome (history, NCS, electromyography)
• Hexosaminidase A deﬁ ciency (white-cell enzyme testing)
Disorders of motor nerves
• Multifocal motor neuropathy (NCS, electromyography, ganglioside GM1 antibodies)
• Chronic inﬂ ammatory demyelinating neuropathy (NCS, lumbar puncture)
• Cramp-fasciculation syndrome (NCS, electromyography)
• Neuromyotonia (antibodies to voltage-gated potassium channels)
• Hereditary spastic paraparesis plus (gene mutation testing)
• Hereditary motor neuropathy with pyramidal features
• Radiculoplexopathy (NCS, electromyography, MRI)
• Paraneoplastic syndrome (serum markers, imaging, bone marrow biopsy sample)
• Heavy metal poisoning (urine or blood screens)
• Mononeuritis multiplex (NCS, electromyography, vasculitic screen, serology)
Disorders of neuromuscular junction
• Myasthenia gravis (acetylcholine receptor antibodies, MuSK antibodies, repetitive 
stimulation, single-ﬁ bre electromyography)
• Lambert-Eaton myasthenic syndrome (repetitive stimulation)
Structural CNS and spinal lesions
• Syringomyelia or syringobulbia (MRI)
• Tabes dorsalis (syphilis serology)
• Multiple sclerosis (MRI, oligoclonal bands, evoked responses) 
• Monomelic spinal muscular atrophy (Hirayama’s disease; electromyography, MRI)
• Lyme disease (Lyme serology)
• Human T-lymphotropic virus-1 (HIV)
Myopathy
• Inclusion body myositis (electromyography, CK, muscle biopsy sample)
• Polymyositis (electromyography, CK, muscle biopsy sample, autoimmune screens)
• Dermatomyositis (electromyography, CK, skin, and muscle biopsy sample)
• Polyglucosan body disease (NCS, electromyography, muscle or nerve biopsy sample)
Endocrine
• Thyrotoxicosis (thyroid function tests, electromyography, muscle biopsy sample)
• Hyperparathyroidism (calcium ion and parathyroid testing)
• Subacute combined degeneration (vitamin B12 concentrations)
• Coeliac disease (serum testing, bowel biopsy sample)
ALS=amyotrophic lateral sclerosis. CK=creatine kinase. NCS=nerve conduction studies. MuSK=muscle-speciﬁ c tyrosine kinase.
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assessment, which usually includes structural imaging 
and neurophysiological and laboratory investigations, to 
reduce the likelihood of an incorrect diagnosis (panel 2).20 
In cases of pure LMN syndromes, genetic testing for 
Kennedy’s disease, an X-linked bulbospinal atrophy, and 
spinal muscular atrophy is important.82 Muscle biopsy 
samples can be of further diagnostic value for excluding 
unusual myopathies such as polyglucosan body disease83 
or for conﬁ rming the presence of ALS by indicating 
atrophy of mixed-ﬁ bre types (ﬁ gure 4A).84
Routine neurophysiological investigations of patients 
with ALS include nerve conduction studies, electro-
myography, and, less commonly, transcranial magnetic 
stimulation.20,85 Nerve conduction studies are essential 
to exclude disorders that mimic ALS, particularly 
demyelinating motor neuropathies.86 Motor nerve 
conduction is normal in the early stages of ALS, but 
in advanced disease the compound muscle action 
potential amplitude becomes reduced, indicating 
denervation.87 Sensory nerve conduction is typically 
normal in patients with ALS, diﬀ erentiating ALS from 
demyelinating neuropathies.88 Prominent abnormalities 
of sensory nerve conduction studies should raise 
suspicion of an alter native diagnosis. In patients 
presenting with predominantly LMN ﬁ ndings, treatable 
disorders such as multifocal motor neuropathy should 
be taken into account, with indication of conduction 
block in at least two motor nerves outside the common 
entrap ment sites.89
In addition to nerve conduction studies, electro-
myography is useful for the identiﬁ cation of LMN loss 
(ﬁ gure 4B). The electromyographical ﬁ ndings indicating 
LMN loss include ﬁ brillation potentials, positive sharp 
waves, and chronic neurogenic changes (ﬁ gure 4C).86,90 
These electromyographical abnormalities have been 
recently incorporated into the revised El Escorial criteria 
to help with the diagnosis of ALS, complementing the 
clinical features of LMN involvement.90 Fibrillation 
potentials and positive sharp waves can be evident in 
muscles that seem clinically normal.86 Electromyography 
can therefore help with an early diagnosis by establishing 
the presence of subclinical LMN involvement.
Motor units that survive can ﬁ re spontaneously as 
fasciculation potentials, clinically visible as involuntary 
muscle twitching—a typical feature of ALS.91 When 
detected in the tongue, fasciculations are highly speciﬁ c 
for ALS.92 The presence of fasciculations in the absence 
of other electromyographical ﬁ ndings should be 
interpreted with caution and can be a sign of less serious 
disorders, especially “benign” cramp-fasciculation 
syndrome.93 Conversely, recently revised consensus 
guidelines (known as the Awaji Island criteria) have 
recommended that fasciculations should be thought to 
be equivalent to ﬁ brillation potentials in individuals with 
clinically suspected ALS.90 Furthermore, fasciculations in 
ALS are complex (“malignant”), indicating re-innervation, 
and have diagnostic importance when combined with 
chronic neurogenic changes (ﬁ gure 4C).
There is discussion about how successful clinicians are 
at diagnosing ALS when using the combined approaches 
of clinical assessment and laboratory investigation. This 
matter was taken into account by the Scottish ALS registry, 
which identiﬁ ed a false positive rate of 8%.15 Other data 
from population-based studies have reported similar false-
positive rates, with a false-negative rate approaching 44%.94,95 
In false-positive cases, the main reasons for diagnostic 
revision included failure to progress, development of 
atypical features, and results of follow-up neurophysiological 
and neuroradiological investigations.15,94 Multifocal motor 
neuropathy was the most frequent disorder misdiagnosed 
as ALS, followed by Kennedy’s disease.94
Advances in neuroimaging
The greatest contribution of neuroimaging to the 
diagnostic pathway in ALS so far has been the ability of 
MRI to exclude alternative pathological causes. However, 
the imaging discipline is evolving, and multimodal 
neuro imaging has made major progress in the 
conﬁ rmation that ALS is a multisystem cerebral 
neurodegenerative disorder.96 The key neuroimaging 
ﬁ ndings, some with potential as biomarkers, are 
discussed in panel 3.
Management and prevention
Riluzole, an inhibitor of glutamate release, is a disease-
modifying (neuroprotective) therapy for patients with 
ALS (panel 4). In two large randomised controlled trials, 
riluzole extended survival of patients by 3–6 months.126–128 
This beneﬁ t seemed greater for management of patients 
in specialised multidisciplinary ALS clinics than in other 
settings,129 with most beneﬁ cial eﬀ ects seen in patients 
with moderate functional impairment.130
Figure 4: Investigation ﬁ ndings in ALS
(A) Biopsy sample of the left vastus lateralis muscle from a patient with ALS, stained with ATPase pH 9·4. The biopsy 
sample highlights grouped atrophic ﬁ bres with both type I and type II ﬁ bres (mixed-type ﬁ bres, encompassed by red 
box). (B) Pathophysiology of motor unit degeneration and reinnervation; with superimposition (C) of ten traces 
demonstrating the typically large, polyphasic, unstable (complex) motor units observed in established ALS (sweep 
duration 50 ms), with late components, indicating some re-innervation. ALS=amyotrophic lateral sclerosis.
A B
C
Surviving motor unit
Degenerated motor unit
Collateral sprouts from
surviving motor axon
reinnervating denervated
muscle ﬁbres
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Symptomatic treatments remain the cornerstone of 
management for patients with ALS (panel 5).28 For 
some patients, these treatments not only alleviate 
symptoms but also improve survival and quality of 
life.131 Optimum care for patients with ALS is provided 
within a multidisciplinary environment where 
physiotherapists, occupational therapists, speech 
therapists, respiratory physicians, gastroenterologists, 
and social workers collaborate to guide symptomatic 
management through the course of disease.132 
Multidisciplinary models of care have developed as a 
predictor of survival, reducing the risk of death by 45% 
at 5 years. Compared with patients managed in a 
general neurology clinic, patients managed in a 
specialised clinic had a better quality of life, possibly 
attributable to more eﬀ ective use of resources, with 
beneﬁ ts derived after a single visit.132
Respiratory function and nutrition are crucial 
symptomatic concerns for patients with ALS, with 
respiratory failure being the main cause of death.81 Expert 
consensus guideline recommendations have been 
developed for key care concerns in ALS, including 
respiratory management, nutrition, and palliative care.81,131 
A positive outlook should be emphasised.133
MRI corticospinal tract hyperintensity
Hyperintensity of the corticospinal tracts as seen on MRI can be 
prominent in ALS,85,97 but this feature is not speciﬁ c to the 
disease (ﬁ gure 5A).
Cerebral atrophy detection with MRI
Voxel-based morphometry has quantiﬁ ed grey and white 
matter to detect cerebral atrophy in patients with ALS98 linked 
to cognitive impairment,99 with notable diﬀ erences in regional 
emphasis between patients with sporadic disease and those 
with familial disease who have a longer life expectancy.100 
3-Dimensional rendering of the brain by use of MRI might also 
serve to highlight focal abnormality (ﬁ gure 6).
Magnetic resonance spectroscopy
The measurement of proton-containing metabolites such as 
N-acetylaspartate (expressed as a ratio with creatine/
phosphocreatine or choline) has served as a marker of neuronal 
loss. Patients with ALS have a reduced primary motor cortex 
N-acetylaspartate to creatine ratio compared with controls,101 
and use of magnetic resonance spectroscopy seems particularly 
sensitive in the detection of upper motor neuron dysfunction, 
distinguishing patients with progressive muscular atrophy 
from those with ALS.102
Diﬀ usion tensor imaging
Diﬀ usion tensor imaging can be used to exploit the sensitivity 
of MRI to identify the direction of water diﬀ usion, which is 
expected to be restricted (ie, anisotropic) within intact neuronal 
pathways and more diﬀ use (isotropic) in regions of reduced 
integrity. Quantiﬁ able measures such as fractional anisotropy 
and mean diﬀ usivity are powerful surrogate markers of 
neuronal pathological changes,103 and inter-connectivity 
between neuronal pathways can be mapped using the allied 
technique of tractography (ﬁ gure 5B).104 Use of diﬀ usion tensor 
imaging can detect reduced fractional anisotropy within the 
corticospinal tract of patients with ALS.105
Functional studies 
Results of PET activation studies with 2-18ﬂ uoro-2-deoxy-D-
glucose and H215O have indicated widespread extramotor 
changes in patients with ALS,106 with frontal deﬁ cits linked to 
neuropsychological impairment,107 providing clear application to 
the emerging clinicopathological overlap between ALS and 
FTD.108 Non-invasive study of brain activation by functional MRI 
exploits diﬀ erences in the resonant properties of 
oxyhaemoglobin versus deoxyhaemoglobin (blood oxygenation 
level dependent [BOLD]-functional MRI). By analysing whole-
brain BOLD-functional MRI activity in the resting state, 
functionally interconnected brain regions can be identiﬁ ed.109 
Results from studies in patients with ALS have shown both 
“default mode” and sensorimotor network activation changes.110 
This technique has the potential to further delineate the 
extramotor cerebral pathological changes in patients with ALS.
Molecular imaging
Receptor ligand PET has been used to study molecular 
mechanisms in ALS. Data from 11C-ﬂ umazenil PET have 
indicated reduced inhibitory GABAergic cortical eﬀ ects in ALS,111 
in keeping with the hypothesis of cortical hyperexcitability as a 
fundamental aspect of ALS pathogenesis.112 Use of the 
benzodiazepine receptor PET ligand 11C-PK11195 revealed 
widespread microglial activation in ALS,113 supported by the 
ﬁ nding of inﬂ ammatory biomarkers in the cerebrospinal ﬂ uid.114 
The pronounced frontotemporal reductions in the binding of 
the 5-HT1A receptor ligand 11C-WAY100635 in patients with 
ALS,115 and data from neuropathological receptor studies that 
revealed similar changes in FTD,116 suggest that serotonergic 
mechanisms warrant further study in relation to pathogenesis. 
Finally, paramagnetic properties of small particles of iron oxide, 
which can be used as intravenous contrast agents, might 
indicate the start of the era of molecular MRI,117 with potential 
to understand inﬂ ammatory mechanisms118 and therapeutic 
stem-cell tracking.119
Detection of presymptomatic markers of disease 
The poor deﬁ nition of the population at risk for sporadic ALS 
impedes attempts to identify an early, presymptomatic 
diagnostic biomarker. Results from a diﬀ usion tensor imaging 
study of presymptomatic patients with a highly penetrant 
dominant SOD1 gene mutation revealed changes in the posterior 
limb of the internal capsule not seen in healthy controls, which 
might be among the earliest detectable changes.120
ALS=amyotrophic lateral sclerosis. FTD=frontotemporal dementia.
Panel 3: Key neuroimaging ﬁ ndings in ALS
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Respiratory failure indicates combined degeneration of 
central respiratory centres and motor neurons contributing 
to the phrenic nerve. Respiratory compromise is commonly 
present at diagnosis in patients with ALS.28 Nocturnal 
hypoxia, and associated symptoms of lethargy, loss of 
concentration, morning headaches, and unrefreshed sleep 
are consequences of central dysfunction. Diaphragmatic 
weakness can be diagnosed with spirometry, with vital 
capacity undergoing a progressive decline over the course 
of disease. Measures of inspiratory muscle strength, such 
as maximum inspiratory pressure and sniﬀ  nasal 
inspiratory pressure, are more accurate predictors of 
respiratory dysfunction than is vital capacity, and might be 
more feasible in patients with substantial facial muscle 
weakness (ie, who are unable to form a tight lip seal).28,81
Although undertaking polysomnography might be the 
optimum approach to identify nocturnal hypoxic 
episodes, nocturnal pulse oximetry is usually adequate 
in patients with ALS.81 Non-invasive ventilation improves 
quality of life in patients with ALS and improves 
survival.134 Guidelines for instituting non-invasive 
ventilation rely on a combination of symptoms that 
Panel 4: Controversy in ALS—clinical trials
Although clinical trials of ALS have been done since the 1980s, riluzole is the only drug of 
proven eﬃ  cacy for treatment of this disorder. The failure of ALS clinical trials to lead to 
substantial beneﬁ ts has been attributed to several potential design problems at preclinical 
and clinical levels:
Preclinical
• Inappropriate mouse model. Until recently, the SOD1 mouse model has been the 
benchmark for testing potential neuroprotectants in ALS.121 However, as SOD1 
mutations account for about 2% of all ALS cases, the mouse model might have little 
relevance to human sporadic disease. Furthermore, this model undergoes a series of 
stereotypical changes that begin with hind limb weakness. The recent development 
of mouse models with mutations in the gene encoding TDP-43 is a potential 
advance in therapeutic development for ALS, providing basic scientists with a new, 
perhaps more relevant, platform for studying novel therapies.122
• Inappropriate timing of introducing drugs and dosing problems. Some investigators 
have studied the eﬀ ects of presymptomatic delivery of drugs on disease onset.123 
Although this timing might contribute towards understanding the subclinical 
processes that underlie motor neuron degeneration, it seems to be of little relevance 
for treatment of sporadic ALS. Many preclinical studies have also examined ultra-high 
doses of drugs that would probably translate into plasma concentrations far beyond 
that tolerable by human patients. Some investigators have advocated that the highest 
tolerable dose should not be assumed to produce the best outcome.124
Clinical
• Trial design. There is increasing need for more eﬀ ective screening of pharmacological 
drugs during phase 2 trials because after this period of clinical development a 
decision is made to proceed with conﬁ rmatory testing (ie, a phase 3 trial) or to reject 
the drug as ineﬀ ective. The distinction between phase 2 and phase 3 trials in ALS 
becomes blurred, because providing preliminary evidence of drug eﬃ  cacy in this 
disease at the phase 2 level is diﬃ  cult. The absence of an eﬀ ective biomarker is a 
major contributing reason. Therefore, the dilemma remains whether to use eﬃ  cient 
statistical strategies for minimising trial duration and sample size, to increase the 
chance of proceeding with a phase 3 trial (ie, higher false-positive rate), or to do 
phase 3 clinical trials tailored as phase 2 clinical trials (ie, higher false-negative rate). 
The latter approach is perhaps one that is now rarely done, given recent advances in 
statistical design.125 Investigators are also proceeding with phase 3 clinical trials, even 
in the absence of preliminary evidence of eﬃ  cacy in human patients.
• Choice of primary endpoint. Changes in the primary endpoint establish whether a trial 
will be successful. The choice of the correct primary endpoint in ALS clinical trials has 
been debated. Trials that use functional scales and measures of strength as primary 
endpoints have dominated the ﬁ eld, whereas trials mainly concerned with improved 
survival of patients have been few and far between recently. The design and clinical 
beneﬁ ts of the former include: smaller sample size, shorter trial duration, and clinically 
meaningful treatment eﬀ ects. Nevertheless, measurement of survival might be the 
only means of determining whether a treatment eﬀ ect truly exists, given the large 
extent of motor neuron loss from the time of symptom onset. For example, riluzole 
has small but signiﬁ cant eﬀ ects on the function of patients, detectable with sample 
sizes far beyond that required to realise its survival beneﬁ t.
ALS=amyotrophic lateral sclerosis. 
Figure 6: 3-Dimensional MRI of a brain of a patient with primary lateral 
sclerosis, as shown from above
Arrows show visibly widened precentral sulci with relative atrophy of the adjacent 
gyri, notably the motor strips. Macroscopic atrophy as seen here is rare in patients 
with typical ALS, but is more frequently noted in those with primary lateral 
sclerosis, who have a predominantly upper motor neuron burden of disease. This 
ﬁ gure highlights the late stage of a corticomotoneuronal process postulated to 
be inherent in ALS more generally. ALS=amyotrophic lateral sclerosis. 
L R
Figure 5: Standard and experimental MRI sequences in patients with ALS 
(A) T2-weighted FLAIR sequence shows hyperintense corticospinal tracts in a 
patient with ALS on this coronal view (arrows), but this feature is neither 
sensitive nor speciﬁ c in the absence of other more obvious clinical symptoms. 
(B) Diﬀ usion tensor tractography is a research-based MRI technique that has 
potential to study extramotor and motor neuronal pathway involvement in ALS 
(superior oblique cut-out brain section viewed from left). In this patient with an 
unusual ALS phenotype that included prominent aphasia, reconstruction of the 
temporal lobe white matter projection ﬁ bres indicated that there were fewer 
ﬁ bres on the left (blue) compared with the right (red) side. ALS=amyotrophic 
lateral sclerosis. FLAIR=Fluid-attenuated inversion-recovery.
A B
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signify respiratory muscle weakness (dyspnoea and 
orthopnoea), along with signs of respiratory muscles 
weakness, including substantial desaturation on 
overnight oximetry, increased partial pressure of carbon 
dioxide (PCO2) of less than 65 mm Hg and reduced 
forced vital capacity of less than 80% or sniﬀ  nasal 
inspiratory pressure of less than 40 cmH2O.28,81 Patients 
with substantial bulbar impairment and sialorrhoea 
might not tolerate non-invasive ventilation, and 
appropriate management of secretions is crucial.28 In 
patients with ALS who are intolerant of non-invasive 
ventilation, when this form of ventilation is no longer 
suﬃ  cient because of progressive respiratory muscle 
weakness, invasive ventilation via tracheostomy is an 
option.81 Although invasive ventilation prolongs survival, 
this approach is rarely used in most countries because of 
the practical challenges involved, the expense, and the 
profound loss of quality of life.135 In terms of symptomatic 
therapy, subcutaneous morphine provides great relief in 
patients who have dyspnoea at rest.81,136
Malnutrition is a key determinant of prognosis.137 The 
development of malnutrition in ALS is multifactorial, 
and includes reduced food intake secondary to dysphagia, 
as well as hypermetabolism.81,138 About 50–60% of patients 
with ALS have a hypermetabolic state,139,140 which seems 
to be stable over the course of the disease and is 
dependent on age, sex, and fat-free mass.139 The increase 
in metabolic rate, as measured by resting energy 
Weakness and disability
• Orthotics (eg, ankle foot orthosis, neck collars)
• Physiotherapy
• Adaptive aids (eg, walking frame, wheelchair)
Dysphagia
• Assessment by speech therapist and dietitian
• Safe swallowing techniques and modiﬁ ed diet
• Insertion of gastrostomy tube
Dyspnoea and poor cough
• Ventilatory support
• Morphine or benzodiazepines 
• Chest physiotherapy
• Suction machine
• Manually assisted coughing techniques
Pain (ie, musculoskeletal pain and cramps, fasciculations 
and spasticity, skin pressure pain caused by immobility)
• Physiotherapy, NSAIDs
• Muscle relaxants (baclofen, botulinum toxin)
• Anticonvulsants (eg, gabapentin)
• Re-positioning and pressure area care
• Opioid drugs
• Pressure-relieving cushions and mattress
Dysarthria
• Assessment by speech pathologist
• Communication aids
• Educate family and caregivers
Cognitive changes (frontal lobe dysfunction or dementia)
• Explain symptomatology to caregivers and family
• Antidepressant therapies
Sialorrhoea
• Anticholinergic antidepressants (eg, amitriptyline)
• Anticholinergic drugs (eg, glycopyrronium bromide)
• Botulinum toxin injections
• Radiation of salivary glands
• Mouth-care products
• Suction
Thickened saliva
• Natural remedies (eg, papaya)
• Ensure adequate hydration
• Saline nebulisers; nebulised N-acetylcysteine
• Suctioning of the mouth
• Mouth care
Emotional lability
• Educate patients with ALS and caregivers
• Amitriptyline
• Benzodiazepines
• Dextromethorphan hydrobromide/quinidine sulfate
Depression and anxiety
• Counselling
• Benzodiazepines
• Antidepressants
Sleep disturbance
• Treat underlying problem
• Respiratory review, non-invasive ventilation
• Benzodiazepines, tricyclic antidepressants
Constipation
• Dietary changes (eg, increase ﬂ uid and ﬁ bre intake)
• Use formulations high in bran, bulk, or ﬁ bre
• Regular oral aperients (Movicol [Norgine, the Netherlands] 
or suppositories).
ALS=amyotrophic lateral sclerosis. Data from Andersen and colleagues81 and Miller and 
colleagues.131
Panel 5: Symptomatic care in ALS
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expenditure, is associated with reduced survival.139 
Although the mechanisms that underlie a hypermetabolic 
state are unclear, dysfunction of muscle mitochondria is 
implicated in the pathogenesis of ALS.141
Insertion of a percutaneous gastrostomy tube ensures 
suﬃ  cient caloric and ﬂ uid intake, and should be oﬀ ered to 
patients who have substantial weight loss, even in the 
absence of dysphagia.81 Implementing a gastrostomy 
should be discussed early in the disease course because 
morbidity increases when vital capacity is less than 50%.142
Attention to the many symptoms that might develop 
during the course of the disease is essential to improve 
the quality of life for patients with ALS (panel 5).143 The 
terminal phase of ALS can be associated with restlessness, 
anxiety, pain, and dyspnoea, and well coordinated multi-
disciplinary palliative care is needed. Finally, patients 
might also seek alternative treatments (panel 6), often 
with little evidence of beneﬁ t for ALS, and at great 
personal ﬁ nancial cost.146
Conclusions
“Let us keep looking, in spite of everything. Let us keep 
searching. It is indeed the best method of ﬁ nding, and 
perhaps thanks to our eﬀ orts, the verdict we will give 
such a patient tomorrow will not be the same we must 
give this man today.” 
Charcot (1889)
By contrast with the previous century of little progress, 
the recent developments in understanding, particularly 
with regards to the genetics, clinical phenotypes, and 
more general pathophysiology of ALS, encourage realistic 
hope that new treatment approaches will emerge.
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